Denali Therapeutics Inc (DNLI) Company Profile & Statistics

Denali Therapeutics Inc
DNLI
(Nasdaq - US)
Open
24.96
-0.09 (-0.36%)
in:usd•As of: Nov 18, 2024 12:38 UTC -5
Open
25.23
High
25.32
Low
24.35

About Denali Therapeutics Inc

CEO

Ryan J. Watts

Headquarters

161 oyster point blvd.

south san francisco, ca 94080, united states

Auditor

Ernst & Young LLP

Employees

445

Share Holders

144

Website

www.denalitherapeutics.com

Industry

biotechnology

Sector

health technology

Company Overview

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.

Denali Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	3.59B
Enterprise Value	3.51B
Enterprise Value/EBITDA (ttm)	-6.70
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.73
Price to Sales (ttm)	10.58
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-32.94%
Return on Invested Capital (ttm)	-33.82%
Return on Assets (ttm)	-30.04%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-523.14M
Net Income Avi to Common (ttm)	-427.49M
Diluted EPS (ttm)	-2.76

Share Statistics

Beta (5Y Monthly)	1.40
52-Week Change	30.07%
S&P500 52-Week Change	29.68%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	143.92M
Dividend Yield	0.00%
Float ⁴	132.55M
% Held by Insiders	7.90%
% Held by Institutions	92.92%

Balance Sheet

Total Cash (mrq)	836.56M
Total Cash Per Share (mrq)	5.81
Total Debt (mrq)	5.63M
Total Debt/Equity (mrq)	0.43%
Current Ratio (mrq)	9.98%
Quick Ratio (mrq)	9.98%
Book Value Per Share (mrq)	9.17

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.56
Free Cash Flow (ytd)	-274.80M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Denali Therapeutics Inc

Trade With A Regulated Broker